Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001502 · ClinicalTrials.gov registry record · Phase 1
A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00001502: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00001502 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001502, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The presence of a highly selective blood-brain barrier (BBB) at the level of the brain capillary endothelium prevents chemotherapeutic agents from attaining therapeutic concentrations at the target site. RMP-7 is a synthetic bradykinin analog which specifically binds to B2 receptors expressed on the brain capillary endothelial cells and preferentially increases capillary permeability within CNS tumors. Carboplatin is an anticancer agent with preclinical and clinical antitumor activity against a variety of brain tumors. A pediatric phase I trial of the combination of RMP-7 and carboplatin will be conducted to determine the maximum tolerated dose of RMP-7 in children with refractory brain tumors.
Interventions
- DRUG RMP-7 and carboplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1996-04 |
| Est. Completion | 2000-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001502
The ClinicalTrials.gov registry entry for NCT00001502 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RMP-7 and carboplatin is the first listed.
NCT00001502 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001502 about?
NCT00001502 is a clinical study titled "A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors". The presence of a highly selective blood-brain barrier (BBB) at the level of the brain capillary endothelium prevents chemotherapeutic agents from attaining therapeutic concentrations at the target site. RMP-7 is a synthetic bradykinin analog which specifically binds to B2 receptors expressed on the...
What is the current status of trial NCT00001502?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 1996-04. Estimated completion is 2000-03.
What interventions are being tested in trial NCT00001502?
The interventions under investigation include: RMP-7 and carboplatin (DRUG).
Who is sponsoring clinical trial NCT00001502?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.